UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 15, 2020
Bionano Genomics, Inc.
(Exact Name of Registrant as Specified in its Charter)
|
Delaware
|
001-38613
|
26-1756290
|
||
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
9540 Towne Centre Drive, Suite 100
San Diego, California
|
92121
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (858) 888-7600
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange
on which registered
|
||
|
Common Stock, $0.0001 par value per share
|
BNGO
|
The Nasdaq Stock Market LLC
|
||
|
Warrants to purchase Common Stock
|
BNGOW
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On October 15, 2020, Bionano Genomics, Inc. (the “Company”) issued a press release announcing, among other things, the Company’s preliminary unaudited
revenue range for the quarter ended September 30, 2020. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit
99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference
into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No.
|
Description
|
|
|
Press Release issued by Bionano Genomics, Inc., dated October 15, 2020.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Bionano Genomics, Inc.
|
||
|
Date: October 15, 2020
|
By:
|
/s/ R. Erik Holmlin, Ph.D.
|
|
R. Erik Holmlin, Ph.D.
|
||
|
President and Chief Executive Officer
(Principal Executive Officer)
|
||
Exhibit 99.1
Bionano Genomics to Report Third Quarter 2020 Financial Results and Host
a Conference Call and Webcast on November 12
SAN DIEGO, October 15, 2020 – Bionano
Genomics, Inc. (NASDAQ: BNGO), a life sciences company that develops and
markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, and through its Lineagen CLIA services business offers a menu of diagnostic services for diagnosing pediatric neuro
developmental disorders, including autism spectrum disorder, today announced that it will host a conference call and live webcast on Thursday, November 12, 2020 at 4:30 p.m. Eastern Time to report financial results for its third quarter ended
September 30, 2020.
On the call, Erik Holmlin, Ph.D., Bionano’s chief executive officer, will provide an update on the business and
the progress of the Lineagen integration, including describing the strategic role that Lineagen plays in advancing the Bionano strategy. Chris Stewart, Bionano’s chief financial officer, who joined the company from Tesla on September 1, will
review the financial details for the third quarter and update the outlook.
Dr. Holmlin commented, “I look forward to giving an update on the progress we are making in all areas of the
business. In addition, on a preliminary basis, I am pleased to report that we currently anticipate our revenue for the third quarter to be in the range of $1.9 million to $2.3 million, in line with analyst expectations.”
Conference Call & Webcast Details
| Date: |
Thursday November 12th
|
| Time: |
4:30 p.m. Eastern Time
|
| Toll Free: |
877-407-0784
|
| International: |
201-689-8560
|
| Conference ID: |
13712129
|
| Webcast: |
http://public.viavid.com/index.php?id=142056
|
To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to
the start of the call. An archived version of the webcast will be available for replay in the Investors section of the Bionano website.
About Bionano Genomics
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visit www.bionanogenomics.com or www.lineagen.com.
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visit www.bionanogenomics.com or www.lineagen.com.
Our revenue expectations for the third quarter are preliminary, unaudited and are subject
to adjustment in the course of our ongoing internal control and review procedures.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of
future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among
other things: our integration of Lineagen into the combined business; our expectations regarding our financial performance; and Bionano’s strategic plans. Each of these forward-looking statements involves risks and uncertainties. Actual results
or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our
business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our
strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; the loss of key members of management and our commercial team; and the
risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual
Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which
they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence
of future events or otherwise.
|
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc. +1 (858) 888-7610 eholmlin@bionanogenomics.com Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC +1 (617) 430-7577 arr@lifesciadvisors.com Media Contact:
Darren Opland, PhD
LifeSci Communications
+1 (617) 733-7668
darren@lifescicomms.com
|
 |